NCT05786924 2025-11-20Phase 1/2 Trial of S241656 in Selected RAS/MAPK Mutation- Positive MalignanciesServierPhase 1/2 Recruiting554 enrolled
NCT02711137 2025-10-21Open-Label Safety and Tolerability Study of INCB057643 in Subjects With Advanced MalignanciesIncyte CorporationPhase 1/2 Terminated137 enrolled 31 charts